# Allo HSCT Using RIC and PTCy for Hematological Diseases

> **NCT05805605** · PHASE2 · RECRUITING · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 56 (estimated)

## Conditions studied

- Acute Myelogenous Leukemia
- Acute Lymphocytic Leukemia
- Biphenotypic Acute Leukemia
- Undifferentiated Leukemia
- Prolymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Plasma Cell Leukemia
- Myelodysplastic Syndromes
- Leukemia, Myeloid
- Myelodysplastic Syndrome With Excess Blasts-1
- Burkitt Lymphoma
- Relapsed T-Cell Lymphoma
- Relapsed Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Marginal Zone Lymphoma
- Follicular Lymphoma
- Myeloproliferative Neoplasm
- Myelofibrosis

## Interventions

- **BIOLOGICAL:** Peripheral Blood Stem Cell Transplant
- **DRUG:** Allopurinol 300 MG
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Bone Marrow Cell Transplant
- **RADIATION:** Total Body Irradiation
- **DRUG:** Sirolimus Pill
- **DRUG:** Mycophenolate Mofetil

## Key facts

- **NCT ID:** NCT05805605
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2027-10-22
- **Final completion:** 2028-10-22
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05805605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05805605, "Allo HSCT Using RIC and PTCy for Hematological Diseases". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT05805605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*